Autres langues ObsEva SA

Actions

Cours en clôture Swiss Exchange Autres places de cotation 00:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
0,006 ^CHF	+36,36 %		+20,00 %	-83,15 %

03/04	ObsEva se retire de la cote de la SIX Swiss Exchange	MT
20/03	ObsEva SA annonce la fin de ses activités	CI

ObsEva to Delist from the SIX Swiss Exchange	03/04
ObsEva SA Announces to Wind-Down the Operations	20/03
ObsEva SA Announces Catarina Edfjäll to Step Down from the Board	20/03
ObsEva to Wind Down, Flags SIX Swiss Delisting	28/02
ObsEva Secures Temporary Moratorium Against Creditors	31/01
ObsEva to File for Moratorium in Geneva, Switzerland	30/11
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals	30/11
ObsEva to Return Global Rights on Ebopiprant to Xoma	30/10/23
Organon Returns Ebopiprant to XOMA	27/10/23
ObsEva Net Loss Narrows in H1	27/09/23
ObsEva SA Reports Earnings Results for the Half Year Ended June 30, 2023	27/09/23
ObsEva Terminates Licensing Deal with Yuyuan BioScience for Oral Oxytocin Receptor	13/07/23
ObsEva Recovers Full Worldwide Rights on Nolasiban	13/07/23
ObsEva SA Announces Termination of Its Sub-Licensing Agreement with Yuyuan Bioscience	13/07/23
SIX Group Makes Index Adjustments Following Review	12/07/23
Morning Briefing - Markt Schweiz	02/05/23
Switzerland's ObsEva Appoints Permanent CEO	02/05/23
Obseva ernennt Fabien de Ladonchamps zum CEO	02/05/23
Aktien Schweiz Schluss: Der Freitag im Plus, die Woche im Minus	28/04/23
ObsEva SA announced that it expects to receive CHF 1.54 million in funding from ObsEva USA Inc.	08/12/22

Aucun résultat pour cette recherche